About Our Lab Group
At St. John’s University, our research lab specializes in non-invasive drug delivery, nanotechnology, oral delivery, 3D printing, targeted drug delivery, pulmonary hypertension, lung cancer, mesothelioma, drug discovery, and repurposing. Our team, comprising graduate and undergraduate students, is dedicated to developing non-invasive therapeutic delivery systems for various medical applications.
Our current projects include enhancing FDA-approved drugs for lung cancer, developing targeted nanoparticles for Non-Small Cell Lung Cancer (NSCLC), creating inhalable carriers for pulmonary hypertension, and producing lipid-based inhalable carriers for cystic fibrosis-related pulmonary infections. We work on dry powder inhalation formulations to improve drug delivery efficiency and patient compliance and explore nose-to-brain delivery methods for treating brain diseases like glioblastoma. In addition to lung and brain delivery, we focus on oral drug delivery systems using FDA-approved polymers, lipids, and excipients to enhance drug solubility, dissolution, and permeability. We use software tools like GastroPlus for pharmacokinetic profile prediction and ZoomLab for formulation optimization. In vivo experiments are crucial for evaluating the efficacy, safety, and pharmacokinetics of our drug delivery systems in animal models.
Our lab fosters interdisciplinary collaboration with groups and investigators in medicinal chemistry, pharmacology, and toxicology, strengthening our research capabilities and outcomes at St. John’s University.
Our current projects include enhancing FDA-approved drugs for lung cancer, developing targeted nanoparticles for Non-Small Cell Lung Cancer (NSCLC), creating inhalable carriers for pulmonary hypertension, and producing lipid-based inhalable carriers for cystic fibrosis-related pulmonary infections. We work on dry powder inhalation formulations to improve drug delivery efficiency and patient compliance and explore nose-to-brain delivery methods for treating brain diseases like glioblastoma. In addition to lung and brain delivery, we focus on oral drug delivery systems using FDA-approved polymers, lipids, and excipients to enhance drug solubility, dissolution, and permeability. We use software tools like GastroPlus for pharmacokinetic profile prediction and ZoomLab for formulation optimization. In vivo experiments are crucial for evaluating the efficacy, safety, and pharmacokinetics of our drug delivery systems in animal models.
Our lab fosters interdisciplinary collaboration with groups and investigators in medicinal chemistry, pharmacology, and toxicology, strengthening our research capabilities and outcomes at St. John’s University.
